Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
Authors:
- Cristina FortunoCFCristina Fortuno
- Kristy LeeKLKristy Lee
- Magali OlivierMOMagali Olivier
- Tina PesaranTPTina Pesaran
- Phuong L. MaiPMPhuong L. Mai
- Kelvin C. de AndradeKAKelvin C. de Andrade
- Laura D. AttardiLALaura D. Attardi
- Stephanie CrowleySCStephanie Crowley
- D. Gareth EvansD. Gareth Evans
- Bing-Jian FengBFBing-Jian Feng
- Ann Katherine Major ForemanAFAnn Katherine Major Foreman
- Megan N. FroneMFMegan N. Frone
Preprint
Abstract
Germline pathogenic variants in TP53 are associated with Li-Fraumeni syndrome (LFS), an autosomal dominant cancer predisposition disorder associated with high risk of malignancy, including early onset breast cancers, sarcomas, adrenocortical carcinomas and brain tumors. Intense cancer surveillance for individuals with TP53 germline pathogenic variants has been shown to decrease mortality; therefore, accurate and consistent classification of variants across clinical and research laboratories is crucial to patient care. Here, we describe the work performed by the Clinical Genome Resource TP53 Variant Curation Expert Panel (ClinGen TP53 VCEP) focused on specifying the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines for germline variant classification to the TP53 gene. Specifications were applied to twenty ACMG/AMP criteria while nine were deemed not applicable. The original strength level for ten criteria was also adjusted due to current evidence. Use of the TP53 -specific guidelines and sharing of clinical data amongst experts and clinical laboratories led to a decrease in variants of uncertain significance from 28% to 12% in comparison with the original guidelines. The ClinGen TP53 VCEP recommends the use of these TP53 -specific ACMG/AMP guidelines as the standard strategy for TP53 germline variant classification.Keywords
All Related Versions
- Published version: Human Mutation, 42 (3), 223.
This publication has 55 references indexed in Scilit:
- Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesisBreast Cancer Research, 2019
- TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counselingFamilial Cancer, 2019
- Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterionHuman Mutation, 2018
- The ACMG/AMP reputable source criteria for the interpretation of sequence variantsGenetics in Medicine, 2018
- Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance ImagingJAMA Oncology, 2017
- TP53Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics DataHuman Mutation, 2016
- The 2016 Li-Fraumeni syndrome cancer spectrum.Journal of Clinical Oncology, 2016
- Revisiting Li-Fraumeni Syndrome From TP53 Mutation CarriersJournal of Clinical Oncology, 2015
- Actionable exomic incidental findings in 6503 participants: challenges of variant classificationGenome Research, 2015
- When mutants gain new powers: news from the mutant p53 fieldNature Reviews Cancer, 2009